What is Chronic Cough?
Chronic cough is a common and troublesome clinical problem and currently there are no effective treatments. While individual specialist cough clinics have been set up in some European countries, there is no formal mechanism to develop common management approaches. Furthermore, the vast majority of clinical trials of novel anti-tussive treatment have been conducted in a limited number of sites in the United Kingdom and United States with little in the way of cough clinical trial infrastructure across Europe. NEUROCOUGH seeks to address this through creating a platform that allows clinicians, together with researchers in academia and five industrial partners, to exchange ideas and facilitate collaborations geared towards improved care and treatment for patients with cough. NEUROCOUGH will place Europe at the forefront of clinical improvements in chronic cough and provide a strong platform for attracting major clinical trials of anti-tussives, thus speeding up drug discovery with the ultimate aim of providing better treatments for patients with chronic cough.
To develop a large, prospective, observational database of patients with chronic cough managed throughout Europe.
This dataset will provide real-life data regarding the current management of chronic cough across Europe to support the clinical audit of clinics across Europe allowing further refinement of existing protocols and evidence based clinical practice guidelines
To promote collaborative research between European specialist cough clinics
To provide a Europe-wide database of carefully phenotyped cough patients providing, for the first time, a Europe-wide registry of ‘clinical trial ready’ chronic cough patients suitable for multi-centre experimental medicine studies and later phase precision medicine clinical trials.
To serve as an important resource of well characterised biological samples suitable for genetic studies and genomic and proteomic analysis.
To undertake detailed statistical analysis to identify distinct cough phenotypes and to develop risk stratification models to define cough patient sub-groups with specific patterns of therapeutic response and disease progression.
To record and define longitudinally the stability of the chronic cough phenotype by recording of core dataset at baseline and 12 months.
The World Health Organisation's International Classification of Diseases is a health care classification system that provides a system of diagnostic codes for classifying diseases. At present chronic refractory cough is not listed as a condition in its own right and cough is regarded as a symptom of other diseases. The NEUROCOUGH Consortium seeks to address this omission by submitting evidence to WHO in support of the inclusion of chronic cough in the next edition, ICD11.
European Lung Foundation
In conjunction with the European Lung Foundation, a Cough Patient Advisory Group has been established to provide input into NEUROCOUGH’s design and implementation based on the priorities and unmet needs of patients. The Patient Advisory Group is supporting the dissemination of the NEUROCOUGH outputs by providing resources in plain language for patients about diagnosis and treatment options, and through public awareness activities. A goal of NEUROCOUGH is to improve awareness of cough amongst primary care clinicians through links with the European Respiratory Society Assembly.
The Patient Advisory Group has provided perspective on study design, recruitment plans and assisted with developing patient information sheets and consent forms and improving ways to recruit participants to clinical trials. The NEURCOUGH Consortium will disseminate and communicate the importance of diagnosing and treating chronic cough through guidelines written in plain English for the benefit of patients, and translate them into the languages of each of the other European partners (German, Dutch, Spanish, Italian, French, Polish, Belgium?)